期刊文献+

In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma 被引量:9

In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma
下载PDF
导出
摘要 Objective: To investigate the synergistic anti-tumor effect of QHF (a Chinese medicine formula with anti- tumor active ingredients, including 800 mg/kg Cinobufotalin, 14 mg/kg Ginsenoside Rg3, 5.5 mg/kg Notoginseng and 100 mg/kg Lentinan) when combined with the chemotherapy drug cisplatin (DDP). Methods: Hepatocellular carcinoma H22 cells were implanted into mice and after the transplants were successfully established the animals were divided into four groups, namely a normal saline(NS) control group, QHF group, DDP group and QHF+DDP group. The tumor growth was monitored and the survival time determined. In vitro studies employing H22 cells used the first three groups, and determined the effects of QHF and DDP on tumor cell cycle distribution, apoptosis and morphologic changes in vitro. Results: QHF significantly inhibited the growth of tumors and prolonged the survival time of mice with hepatocellular carcinomas. QHF combined with DDP could attenuate DDP-induced leucopenia, spleen and thymus atrophy and other indicators of toxicity. The inhibition rate of tumor growth reached 82.54% with QHF+DDP, and QHF prolonged the life span of DDP-treated mice by 66.83%. In the in vitro experiments tumor cells showed morphological changes characteristic of apoptosis by both light and transmission electron microscopy in the QHF group, and the apoptosis rate was 33.85%. Moreover, the proportion of cells in the G0/G1 phase was increased and those in the S-phase decreased. Conclusion: QHF combined with DDP could significantly inhibit tumor growth, induce the apoptosis of tumor cells and effectively attenuate DDP toxicity. Objective: To investigate the synergistic anti-tumor effect of QHF (a Chinese medicine formula with anti- tumor active ingredients, including 800 mg/kg Cinobufotalin, 14 mg/kg Ginsenoside Rg3, 5.5 mg/kg Notoginseng and 100 mg/kg Lentinan) when combined with the chemotherapy drug cisplatin (DDP). Methods: Hepatocellular carcinoma H22 cells were implanted into mice and after the transplants were successfully established the animals were divided into four groups, namely a normal saline(NS) control group, QHF group, DDP group and QHF+DDP group. The tumor growth was monitored and the survival time determined. In vitro studies employing H22 cells used the first three groups, and determined the effects of QHF and DDP on tumor cell cycle distribution, apoptosis and morphologic changes in vitro. Results: QHF significantly inhibited the growth of tumors and prolonged the survival time of mice with hepatocellular carcinomas. QHF combined with DDP could attenuate DDP-induced leucopenia, spleen and thymus atrophy and other indicators of toxicity. The inhibition rate of tumor growth reached 82.54% with QHF+DDP, and QHF prolonged the life span of DDP-treated mice by 66.83%. In the in vitro experiments tumor cells showed morphological changes characteristic of apoptosis by both light and transmission electron microscopy in the QHF group, and the apoptosis rate was 33.85%. Moreover, the proportion of cells in the G0/G1 phase was increased and those in the S-phase decreased. Conclusion: QHF combined with DDP could significantly inhibit tumor growth, induce the apoptosis of tumor cells and effectively attenuate DDP toxicity.
出处 《The Journal of Biomedical Research》 CAS 2010年第2期161-168,共8页 生物医学研究杂志(英文版)
基金 supported by general projects of Hubei Provincial Health Department (No 2005-455-33)
关键词 Chinese medicine ingredients QHF hepatocellular carcinoma CISPLATIN apoptosis Chinese medicine ingredients, QHF, hepatocellular carcinoma, cisplatin, apoptosis
  • 相关文献

参考文献11

  • 1王阶,郭丽丽,杨戈,王永炎.方剂配伍理论研究方法及研究前景[J].世界科学技术-中医药现代化,2006,8(1):1-5. 被引量:37
  • 2Qin LX,Sun HC,Tang ZY.Development in Primary Carcinoma of the Liver-Hong Kong-Shanghai International Liver Congress2006Summary[].Chinese Journal of Surgery.2006
  • 3Huo TI,Huang YH,Wu JC.Percutaneous ablation therapy for hepatocellular carcinoma:current practice and future perspectives[].Journal of the Chinese Medical Association.2005
  • 4Chan FS,Ng KK,Poon RT,Yuen J,Tso WK,Fan ST.Duodeno pleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma[].Asian Journal of Surgery.2007
  • 5Jasinghe VJ,Xie Z,Zhou J,Khng J,Poon LF,Senthilnathan P,et al.ABT-869,a multi-targeted tyrosine kinase inhibitor,in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft[].Journal of Hepatology.2008
  • 6Lam VW,Ng KK,Chok KS,Cheung TT,Yuen J,Tung H,et al.Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma[].Journal of the American College of Surgeons.2008
  • 7Du GH.Studies of Chinese medicine compound active ingredient group[].Proprietary Chin Med.2002
  • 8Zou XH,Zhang KH.Molecular mechanisms of anti-tumor progress[]..2005
  • 9Francica G,Marone G.Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a cooled-tip needle: a preliminary clinical experience[].European Journal of Ultrasound.1999
  • 10Fontana R J,Hamidullah H,Nghiem H,et al.Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation[].Liver Transplantation.2002

二级参考文献10

共引文献36

同被引文献92

引证文献9

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部